RxDoctor Payments Data

Erin Batin, NP

Nurse Practitioner · West Valley City, UTNPI 1245780808

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 110 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$841
  • Johnson & Johnson$182
  • Takeda Pharmaceuticals U.S.A., Inc.$164
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$128
  • Pfizer$103
  • Aimmune Therapeutics, Inc.$97
  • plus $538 from 14 others

What the payments were for

  • Food & beverage$1,97796%
  • Education$764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,053 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$8,731
Medicare patients
62
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase12$39,313
Ursodiol17$6,470
Omeprazole211$3,990
Colestipol Hcl23$3,056
Colesevelam Hcl18$2,196
Balsalazide Disodium14$2,163
Budesonide DrBudesonide15$2,041
Famotidine86$1,344
Lansoprazole46$895
Pantoprazole Sodium62$548
Esomeprazole Magnesium20$407
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$383
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$352
Sucralfate22$301
Hydroxyzine Hcl15$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$97$39,31312 claims
SandozLansoprazole$15$89546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →